Form 4 for RGNX REGENXBIO Inc.
Accepted 2022-07-15 00:00:00 ET · period of report 2022-07-13 · accession 0001562180-22-005681 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-07-15 | 2022-07-13+ | RGNX | Vasista Vittal | CFO | S - Sale | $30.01 | -4,800 | 157.6K | -3% | -$144.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-07-13 | S | D | 4,332 | $30.01 | 158,108 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $30.0000 to $30.0065. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2022-07-14 | S | D | 468 | $30.00 | 157,640 | D | — | — |